Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage

This study has been terminated.
(Business decision)
Sponsor:
Information provided by (Responsible Party):
Healthpoint
ClinicalTrials.gov Identifier:
NCT01108523
First received: April 20, 2010
Last updated: October 9, 2013
Last verified: October 2013
  Purpose

This study evaluates HP828 in the management of moisture associated skin damage after 15 days of use.


Condition Intervention Phase
Skin Abnormalities
Device: HP828-101
Phase 0

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label Evaluation of the Effects of HP828-101 in the Management of Moisture Associated Skin Damage in Adults

Further study details as provided by Healthpoint:

Primary Outcome Measures:
  • Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 15. [ Time Frame: 15 Days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 4, 8, and 12. Proportion of Subjects With no Denuded Skin Area at Day 4, 8, 12, and 15. Pre- and Post-Treatment Surveys [ Time Frame: 4, 8, 12, and 15 days ] [ Designated as safety issue: No ]

Enrollment: 7
Study Start Date: April 2010
Study Completion Date: February 2012
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HP828-101
HP828-101 Experimental Formulation
Device: HP828-101

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • - The informed consent document must be read, signed, and dated by the subject or the subject's legally authorized representative before conducting any study procedures or exams. In addition, the informed consent document must be signed and dated by the individual who consents the subject before conducting Visit 1. A photocopy of the signed informed consent document must be provided to the subject or subject representative, and the original signed document placed in the subject's chart. If the subject is unable to read or sign the informed consent, or unable to comprehend the information provided in the consent process, a legal guardian, decision making proxy, or next of kin must provide written consent, and if possible, subject must verbally assent to receiving an experimental treatment for their wound.
  • Are 18 years of age or older, of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
  • Are expected to remain in the Nursing Home or long-term acute-care (LTAC) for the duration of the study (15 days).
  • Have moisture associated skin damage including denuded skin or ulceration, where:

    • the damage has been present for at least 2 days but less than 6 weeks
    • the area of denudation (target wound) measures greater than or equal to 2 and less than or equal to 64 cm2 in total area
    • the area of total damage may be greater than 64 cm2
  • Are able to verbally respond to the Pre- and Post- Treatment Survey.
  • Women of child-bearing potential may participate in the study if they have a negative urine pregnancy test and use adequate birth control, as determined by the Investigator.
  • Are capable of maintaining adequate nutritional intake during the study

Exclusion Criteria:

  • Have more than 64 cm2 of denuded area.
  • Have a full-thickness target wound, or a full-thickness wound within 4 cm of any target wound area.
  • Have clinical evidence of bacterial or fungal infection of the target wound area.
  • Have, within the area of moisture damaged skin, any tunneling, sinus tracks, shear injury, arterial occlusive disease, or bony prominence or joint with the exception that target wounds may be over dorsal spinous processes, coccyx, ischial tuberosities, or sacroiliac joints.
  • Are moribund, or have a severe burn, debilitating immunodeficiency disorder, significant hematologic disorder, metastatic malignancy, uncontrolled diabetes mellitus, or any medical conditions that, in the opinion of the Investigator, places the subject at risk for the study or incapable of healing.
  • Are known to have acrodermatitis enteropathica (zinc deficiency).
  • Are being treated currently with systemic steroids, immunosuppressive agents, radiation, or chemotherapy.
  • Have been treated with enzymatic debridement to the target wound area within 2 days prior to enrollment.
  • Have a known sensitivity to ingredients of HP828-101.
  • Are using or have used another investigational agent (not including devices such as hearing aids, pace makers, etc.) within 30 days prior to Visit 1.
  • The Medical Monitor may declare any subject ineligible for a valid medical reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01108523

Locations
United States, Texas
Golden Acres
Dallas, Texas, United States, 75228
Sponsors and Collaborators
Healthpoint
Investigators
Study Chair: Herbert B Slade, MD Healthpoint
Principal Investigator: Neeta Nayak, MD Golden Acres
  More Information

No publications provided

Responsible Party: Healthpoint
ClinicalTrials.gov Identifier: NCT01108523     History of Changes
Other Study ID Numbers: 828-101-09-017
Study First Received: April 20, 2010
Results First Received: October 9, 2013
Last Updated: October 9, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Healthpoint:
Moisture Associated Skin Damage

Additional relevant MeSH terms:
Skin Abnormalities
Congenital Abnormalities
Skin Diseases

ClinicalTrials.gov processed this record on October 23, 2014